Flagship Harbor Advisors LLC grew its holdings in shares of Cigna Corp (NYSE:CI) by 13.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,089 shares of the health services provider’s stock after acquiring an additional 133 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Cigna were worth $171,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of CI. Lowe Wealth Advisors LLC purchased a new stake in shares of Cigna in the first quarter valued at approximately $34,000. Truvestments Capital LLC purchased a new stake in shares of Cigna in the 1st quarter valued at $37,000. C J Advisory Inc purchased a new stake in shares of Cigna in the 1st quarter valued at $40,000. Lavaca Capital LLC purchased a new stake in shares of Cigna in the 1st quarter valued at $40,000. Finally, Trustcore Financial Services LLC purchased a new stake in Cigna during the 1st quarter worth about $49,000. 87.64% of the stock is currently owned by hedge funds and other institutional investors.
Cigna stock traded down $2.48 during midday trading on Friday, hitting $153.30. The stock had a trading volume of 1,788,528 shares, compared to its average volume of 1,831,373. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.84. The business has a fifty day moving average price of $167.70 and a 200 day moving average price of $165.11. The stock has a market cap of $58.82 billion, a P/E ratio of 10.78, a P/E/G ratio of 0.79 and a beta of 0.70. Cigna Corp has a 12 month low of $141.95 and a 12 month high of $226.60.
A number of research analysts have recently commented on the company. Morgan Stanley dropped their price objective on Cigna from $241.00 to $207.00 and set an “overweight” rating on the stock in a report on Friday, July 12th. Goldman Sachs Group downgraded Cigna from a “conviction-buy” rating to a “buy” rating in a report on Friday, May 3rd. Sanford C. Bernstein upgraded Cigna from a “market perform” rating to an “outperform” rating and set a $205.00 price objective on the stock in a report on Tuesday, August 6th. Raymond James increased their price objective on Cigna from $185.00 to $190.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, Zacks Investment Research downgraded Cigna from a “buy” rating to a “hold” rating and set a $164.00 price objective on the stock. in a report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $214.55.
Cigna Company Profile
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Read More: What is a price target?
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.